SCHEMBL6794482

SCHEMBL6794482

CC1(C(O)c2ccc(-c3cccc(C#N)c3)cc2)NC(=O)NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.49
AR P10275 1/20 0.42
CHEK1 O14757 1/20 0.41
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
PTPN5 P54829 1/20 0.39
XDH P47989 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
ADAMTS4 O75173 1/20 0.39
GRIA2 P42262 1/20 0.38
GRIA4 P48058 1/20 0.38
MCHR1 Q99705 2/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
MMP2 P08253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793038 0.88 ALDH1A1 (0.41) PGRMMP12MMP13GRIA2GRIA4
SCHEMBL8343005 0.83 MMP3 (0.48) MMP2
SCHEMBL8339982 0.83 PGR (0.41) PGRMMP13MMP2
SCHEMBL6791227 0.82 MMP2 (0.41) MMP2
SCHEMBL6789361 0.82 MMP2 (0.41) MMP2
SCHEMBL6791153 0.82 MMP2 (0.41) MMP2
SCHEMBL6835790 0.82 FFAR1 (0.41) PGRMMP13MMP2
SCHEMBL6792441 0.82 TDP2 (0.40) MMP2
SCHEMBL6919077 0.81 S1PR3 (0.34) PGRAR
SCHEMBL6792382 0.80 PGR (0.48) PGRCHEK1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 PGR 746/4885AR 2163/4885CHEK1 4849/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PGR 860/4885AR 2653/4885CHEK1 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.